Immunologic Factor
Janux Shares Surge Over 200% on Promising Early Signs of PSA Response in Prostate Cancer Treatment
Prostate-Specific Antigen, Janux, JANX007, Malignant neoplasm of prostate
Interchangeable Humira Biosimilar Simlandi Joins Market Battle with Unique High-Concentration Formula
Simlandi, interchangeable, Biosimilars, Market
Novavax Secures $400 Million Settlement with Gavi to Resolve COVID-19 Vaccine Contract Dispute
Gavi, Novavax, Settlement and Resettlement
FDA Approves Xolair (Omalizumab) for Reducing Severe Outcomes from Multiple Food Allergies
Xolair, United States Food and Drug Administration, omalizumab, Hypersensitivity, Food, Reduced, Severe (severity modifier)
After Incyte’s commercial buy, Novartis shells out 2.7B for cancer specialist MorphoSys
Importal, MorphoSys, Acquisition (action), Incyte
J&J’s Nipocalimab Demonstrates Positive Phase III and Phase II Results in Autoimmune Disorders
Nipocalimab, Sjogren’s Syndrome, Johnson and Johnson, Autoimmune Diseases, Myasthenia Gravis, Generalized, Clinical Research, Erythroblastosis, Fetal
GSK details Blenreps PhIII combo winas it hopes to stage a turnaround in multiple myeloma
Multiple Myeloma, Blenrep, turnaround, GSK’s, Progression-Free Survival, Combined
Gilead Expands Arcus Collaboration with $320M Equity Investment
Investments, Arcus, Gilead, Combined, Phase 3 Clinical Trials
Sanofi, Regeneron Win Dupixent Label Expansion to Treat Eosinophilic Esophagitis
Eosinophilic esophagitis, Dupixent, Child, Treatment intent, sanofi, Regeneron
Lilly’s Donanemab Poised for FDA Decision amid Embraced Alzheimer’s Disease Competition
Alzheimer’s Disease, Donanemab, United States Food and Drug Administration, Lilly’s